← Back to Search

Cancer Screening Methods for Prostate Cancer

N/A

Waitlist Available

Led By Christine D Berg

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Men who at the time of randomization are less than 55 or greater than or equal to 75 years of age

Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up events through 13 years of follow-up or through december 31, 2009; median follow-up 12.0 years.

Awards & highlights

No Placebo-Only Group

Summary

This trial looks at different ways of screening for common cancers to see if any of them can reduce the number of people who die from these cancers.

Who is the study for?

This trial is for men aged below 55 or above 75, who haven't used Proscar/Propecia/finasteride in the last 6 months. It's not for those with prior cancers (except certain skin cancers), recent colon cancer screenings, major organ removals due to cancer, or current participation in other cancer trials. Men must be willing to sign consent and have had no more than one PSA test in three years.

What is being tested?

The study tests if screening methods like questionnaires, lab biomarker analysis, and medical exams can help detect prostate cancer early and reduce death rates. The focus is on finding better ways to identify prostate cancer at an early stage through various screening techniques.

What are the potential side effects?

Since this trial involves non-invasive screening procedures rather than medication or surgery, side effects are minimal but may include discomfort from medical examinations or anxiety from test results.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a man under 55 or over 75 years old.

Select...

I am currently being treated for cancer, not including basal or squamous skin cancer.

Select...

I have had cancer of the colon, rectum, lung, or prostate before.

Select...

I have had surgery to remove my entire colon, one lung, or my entire prostate.

Select...

I have taken Proscar, Propecia, or finasteride in the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ events through 13 years of follow-up or through december 31, 2009; median follow-up 12.0 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~events through 13 years of follow-up or through december 31, 2009; median follow-up 12.0 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and events through 13 years of follow-up or through december 31, 2009; median follow-up 12.0 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Prostate Cancer Death Rates

Prostate Cancer Deaths

Secondary study objectives

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Death Rates From All Causes

Deaths From All Causes

+12 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: ControlActive Control1 Intervention

Participants receive standard medical care. Participants complete a DHQ at baseline.

Group II: Prostate ScreeningActive Control3 Interventions

Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.

0 / 5Eligibility criteria met